Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: family (674), relations (312), loved ones (72)

Leg artery bypass (fem-pop bypass) - patient information

Description: Information about an arterial bypass (also known as a fem-pop bypass) - an operation to create a new route for blood
Url: /Media/UHS-website-2019/Patientinformation/Cardiovascular-and-thoracic/Leg-artery-bypass-fem-pop-bypass-1659-PIL.pdf

Femoral endarterectomy - patient information

Description: information about having a femoral endarterectomy to improve the circulation to the legs
Url: /Media/UHS-website-2019/Patientinformation/Cardiovascular-and-thoracic/Femoral-endarterectomy-1658-PIL.pdf

Endovascular aneurysm repair (EVAR) - patient information

Description: Information about endovascular aneurysm repair (EVAR
Url: /Media/UHS-website-2019/Patientinformation/Cardiovascular-and-thoracic/Endovascular-aneurysm-repair-EVAR-1657-PIL.pdf

Carotid endarterectomy - patient information

Description: Information about having a carotid endarterectomy
Url: /Media/UHS-website-2019/Patientinformation/Cardiovascular-and-thoracic/Carotid-endarterectomy-1656-PIL.pdf

Abdominal aortic aneurysm repair - patient information

Description: Information about abdominal aortic aneurysm repair
Url: /Media/UHS-website-2019/Patientinformation/Cardiovascular-and-thoracic/Abdominal-aortic-aneurysm-repair-1654-PIL.pdf

Avelumab(800mg)

Description: Chemotherapy Protocol BLADDER CANCER AVELUMAB (800mg) Regimen  Bladder Cancer - Avelumab Indication  Avelumab is indicated as monotherapy for the first-line maintenance
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Avelumab800mg.pdf

Pembrolizumab2mg/kg

Description: Chemotherapy Protocol LUNG CANCER Pembrolizumab (2mg/kg) Regimen • NSCLC – Pembrolizumab (2mg/kg) Indication • Pembrolizumab is recommended as an option for treating
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab2mgkg.pdf

Pembrolizumab_400mg (NSCLC)

Description: Chemotherapy Protocol LUNG CANCER Pembrolizumab (400mg) Regimen • Lung Cancer – Pembrolizumab (400mg) Indication The treatment of untreated PD-L1 positive metastatic non
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-400mg.pdf

Pembrolizumab 200mg (NSCLC)

Description: Regimen Chemotherapy Protocol LUNG CANCER Pembrolizumab (200mg) • Lung Cancer – Pembrolizumab (200mg) Indication The treatment of untreated PD-L1 positive metastatic non
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-200mg.pdf

Pembrolizumab 400mg (bladder)

Description: Chemotherapy Protocol BLADDER CANCER Pembrolizumab (400mg) Regimen • Bladder – Pembrolizumab (400mg) Indication • Pembrolizumab is indicated for locally advanced (ie T4b any N
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-400mg.pdf

201 to 210 of 245

Previous … 19 20 21 22 23 … Next